Chapter 4: Chemistry of Behavior: Neurotransmitters & Drugs

Chemistry of Behavior: Neurotransmitters & Drugs details the interaction between ligands and receptors, distinguishing between ionotropic (fast) and metabotropic (slow) receptors, and defines key pharmacological concepts such as agonists, antagonists, inverse agonists, and partial agonists. A major portion of the chapter categorizes the brain's neurotransmitters, including amino acids like glutamate (excitatory) and GABA (inhibitory); amines such as acetylcholine, dopamine, norepinephrine, and serotonin; neuropeptides like opioids; and gas transmitters like nitric oxide which function through retrograde signaling. The discussion transitions to pharmacodynamics and pharmacokinetics, analyzing drug-receptor interactions through binding affinity and efficacy, and interpreting dose-response curves to determine potency and safety (therapeutic index). The text explains how the body adapts to repeated drug exposure through metabolic and functional tolerance, including the up-regulation and down-regulation of receptors, as well as the phenomenon of sensitization. It systematically reviews major drug classes used for psychiatric treatment and recreation: antipsychotics that target dopamine receptors to treat schizophrenia; antidepressants (MAO inhibitors, tricyclics, and SSRIs) that modulate monoamines; anxiolytics like benzodiazepines that enhance GABAergic inhibition; and potent analgesics such as opiates that bind to receptors in the periaqueductal gray. The chapter also covers recreational substances, detailing the mechanisms of cannabinoids (THC and anandamide), stimulants (nicotine, cocaine, and amphetamine) that often manipulate dopamine reuptake or release, and the biphasic effects of alcohol on neural tissue. Finally, it addresses the complex nature of substance abuse and addiction, evaluating models ranging from moral and disease perspectives to physical dependence and positive reward theories. This section highlights the critical role of the dopaminergic reward pathway extending from the ventral tegmental area to the nucleus accumbens and concludes by surveying treatment strategies, including anti-withdrawal medications and potential vaccines.